Double metastatic cancer with lung and urothelial carcinoma responding to enfortumab vedotin: a case report and review of the literature Authors: Magali Ravoire, Léa Vazquez Published: 2025 ABSTRACT AbstractBackgroundFor patients with metastatic lung adenocarcinoma, systemic therapy with platinum-based chemotherapy associated with immunotherapy is the standard of care. The treatment decision seems to be more difficult with a second cancer occurrence during the treatment course. Here we report a rare case of concomitant urothelial and lung adenocarcinoma in which both tumors responded to enfortumab vedotin, an antibody–drug conjugate targeting nectin-4—a response not previously described in this setting.Case presentationWe describe a 74-year-old white male who was diagnosed with metastatic lung adenocarcinoma (KRAS G12C mutation, PD-L1 5%) and developed locally advanced urothelial carcinoma during first-line treatment for lung cancer. The second urothelial nodal recurrence following platinum-based chemotherapy leads to enfortumab vedotin initiation. Enfortumab vedotin, an antibody–drug conjugate, was initiated under early access authorization and produced a complete response of urothelial lesions and partial response of lung lesions. Treatment was discontinued after 16 months due to grade 2 neuropathy and persistent complete response.ConclusionThis exceptional case demonstrates a prolonged dual response of urothelial and lung adenocarcinomas to enfortumab vedotin. It highlights the potential role of nectin-4–targeted therapy beyond urothelial carcinoma and supports further investigation of this agent in non-small cell lung cancer.Keywords: Urothelial carcinoma, Lung adenocarcinoma, Enfortumab vedotin, Exceptional response Background Metastatic urothelial carcinoma is a poor long-term survival disease with approximately 10–15% of metastatic disease patients at diagnosis [4]. First-line treatment of metastatic urothelial carcinoma remains cisplatin-based chemotherapy over 20 years ago. In recent years, several clinical trials had investigated the benefits of several novel compounds as fibroblast growth factor receptor inhibitor or antibody–drug conjugate-based therapeutics, leading to several treatment approvals in second or more treatment lines [5]. For urothelial cancer, the first-approved antibody–drug conjugate (ADC) was enfortumab vedotin (EV). EV, a completely humanized monoclonal antibody, targets Nectin-4, a cell adhesion molecule, and is coupled to the microtubule-disrupting compound monomethyl auristatin E (MMAE) [6]. Nectin-4 is overexpressed in several malignancies including urothelial, breast, pancreatic, and lung cancer [7]. EV is internalized by cells after binding to Nectin-4; it is then cleaved by proteolytic enzymes leading to MMAE release. The cellular microtubule network is then destroyed by MMAE inducing cell cycle arrest and cell death by inhibition of microtubule polymerization [8]. Nectin-4 expression is correlated with disease progression and a poor prognosis in hepatocellular carcinoma, pancreatic, and gastric cancers [9–11]. In NSCLC, Nectin-4 might play a significant role in carcinogenesis [12] but ADC targeting Nectin-4 was never considered in NSCLC. Lung cancer is the most frequent cause of cancer in developed countries and adenocarcinoma is the most common subtype of non-small cell lung cancer (NSCLC) in recent years [1]. Since KEYNOTE-189 clinical trial, the combination of carboplatin/pemetrexed and pembrolizumab is one of the standard of care for metastatic NSCLC with both nonsquamous and squamous histologic findings [2]. The incidence of second primary cancer in France is estimated at 7.3%, and the risk of second cancer is 1.36× greater than for the rest of the population. However, the risk of developing a second cancer depends strongly on sex, age, and primary cancer site [3]. EV was FDA-approved on 18 December 2019 for the treatment of patients with locally advanced or metastatic urothelial cancer. This accelerated approval was based on tumor response rate and durability of response in the pivotal trials EV-101 [13]. We present a case of a white male patient with metastatic lung adenocarcinoma receiving platinum-based chemotherapy with pembrolizumab. During treatment course, renal lesion leads to metastatic urothelial carcinoma diagnostic. Metastatic second line treatment for urothelial carcinoma with EV leads up to long-lasting complete response for both cancers. Case presentation A 74-year-old white man, ECOG PS 0, with a past medical history of diabetes and right hemiparesis stroke-induced, presented to our cancer institute for lung cancer suspicion. Lung adenocarcinoma stage IV (T2 N2 M1 with homolateral pulmonary metastases) was diagnosed as PD-L1 positive by IHC (22C3 antibody, tumor proportion score 5%) and only G12C mutation of KRAS (detected using the IPLEX HS Lung Panel (Agena Bioscience), a mass spectrometry-based sequencing assay with 1% sensitivity). Platine-based chemotherapy associated with immunotherapy was initiated. The patient was treated with four cycles of carboplatin (area under the curve (AUC) of 5 according to the Calvert formula), pemetrexed (500 mg/m2), and pembrolizumab (200 mg) every 3 weeks. Maintenance therapy with pemetrexed (500 mg/m2 the first cycle, 400 mg/m2 the second, and 300 mg/m2 the others) and pembrolizumab (200 mg) every 3 weeks was initiated then for five cycles. An fluorodeoxyglucose (FDG)-positron emission tomography (PET) scan performed before the initiation of platinum-based chemotherapy and pembrolizumab showed hypermetabolic activity in lung, renal, and nodal lesions. Due to general condition deterioration and major asthenia, pemetrexed was stopped, and pembrolizumab (200 mg) was continued for two cycles. Pembrolizumab was discontinued due to nodal involvement increase and the onset of renal damage. Abnormal renal hilar lymph nodes were biopsied and revealed a stage IV renal urothelial carcinoma (T4N2Mx). Immunohistochemistry showed positivity for GATA3 and CK7 and negativity for TTF1, confirming urothelial origin. Considering nodal involvement and concomitant metastatic lung adenocarcinoma, surgery was denied. A combination of chemotherapy drugs with gemcitabine (1000 mg/m2, D1-8 Q21 days) and carboplatin (AUC of 5, D1 Q21 days) for six 21-day cycles provided partial response for 11 months. Computed tomography revealed retroperitoneal lymph node recurrence (+30% according to RECIST criteria), while lung lesions (primary and metastatic) remained stable. Similar combination drugs (carboplatin AUC of 3 and gemcitabine 1000 mg/m2) with adapted dosage (−40%) every 2 weeks was initiated for eight cycles. Partial response was obtained on nodal lesions. Maintenance treatment was introduced with avelumab (800 mg) every 2 weeks. After 2 months of immunotherapy treatment, computed tomography (CT)-scan results showed renal and periaortic lymph nodes recurrence. Despite the lack of marketing authorization (MA), EV (1.25 mg/kg every week) was initiated under an early access authorization to the treatment. After 12 injections every week, CT-scan results revealed renal and nodal complete response associated with primary lung lesion and lung metastasis stability. Nevertheless, grade 2 skin toxicity appeared under crusting lesions in the lower limbs, without mucosal involvement. Allergic reaction was treated with antihistaminic and local corticosteroids. Consequently, EV dosage was decreased (1 mg/kg) for the following three injections. Short improvement was reached, but pruritic and erythematous grade 2 blistering skin lesions reappeared few days later, despite oral antihistaminic and local corticosteroids treatment. Antibiotherapy (doxycycline 100 mg BID for 3 weeks) and oral corticosteroids (10 mg daily for 10 days) were initiated, and EV administration was temporarily withheld. Skin lesions improved within 21 days and EV dosage was decreased once more (0.75 mg/kg) for all subsequent injections. The CT scan performed every 3 months indicated renal and nodal complete response and partial response on lung lesions (Fig. 1). A total of 16 months after the first enfortumab vedotin injection, the treatment was discontinued due to the achievement of a complete radiologic response and the development of grade 2 peripheral neuropathy. A follow-up FDG-PET scan conducted 2 months after enfortumab vedotin discontinuation demonstrated a complete metabolic response. The key steps of patient management are shown in Fig. 2. CT scan evaluation of renal lesion before enfortumab vedotin (on the left) and 1 year after treatment initiation (on the right) Management patient key steps Discussion and conclusion Last year, the EV-301 trial demonstrated superior efficacy over chemotherapy in patients with advanced urothelial carcinoma previously treated with platinum containing regimen and PD-1/PD-L1 inhibitors [14]. Compared with second line chemotherapy, EV significantly improved overall survival (median 12.88 versus 8.97 months) and progression-free survival (PFS) (median 5.55 versus 3.71 months) [14]. Furthermore, in a recent retrospective European multicenter real-world patient cohort, median PFS was 5.0 months for patients with ECOG PS 0–1 [15]. The patient presented here was diagnosed during pembroluzimab treatment for his stage IV lung cancer and received two lines of platinum-based chemotherapy with immunotherapy maintenance (avelumab) before nodal recurrence leading to EV initiation. A few weeks before the last recurrence, early access authorization was granted to EV for patients with advanced urothelial carcinoma who had relapse of disease after platinum-containing chemotherapy. Despite lung cancer history, early access to EV was accepted for this patient. The treatment performed a complete response for urothelial carcinoma and a partial response for lung carcinoma during at least 12 months (PFS) for this patient. For stage IV lung adenocarcinoma, the patient received platinum, pemetrexed and pembrolizumab combination thereupon pembrolizumab maintenance for two cycles before the urothelial carcinoma development. Platinum-based chemotherapy for urothelial carcinoma allowed partial response of primary and metastatic lung lesions as well as EV initiated 1 year ago. In KEYNOTE-189, the median PFS for patient with metastatic nonsquamous NSCLC without sensitizing EGFR or ALK mutations receiving in first-line treatment pemetrexed, platinum drug and pembrolizumab, was 8.8 months [16]. In our patient, the treatment achieved a partial response with primary and metastatic lesion size reduction but need to be stopped after 6 months (four cycles of pemetrexed/carboplatin/pembrolizumab, four cycles of pemetrexed/pembrolizumab, and two cycles of pembrolizumab alone) to begin urothelial carcinoma treatment. PFS for his metastatic lung NSCLC is at least 41 months. Note that patient received two platinum-based regimens during the last 41 months. Nevertheless, in the Keynote-189 trial, the patient receiving platinum-based chemotherapy without pembrolizumab had an even shorter PFS (4.9 months) [16]. Our patient did not receive platinum-based chemotherapy for 16 months. Although EV is not currently approved for lung cancer or other ADC indications, studies revealed that nectin-4 (the EV protein target) is overexpressed and served as a tumor associated inducer in various malignant tumor including lung cancers [6, 12]. Since several studies exhibit the involvement of nectin-4 in various facets of cancer such as angiogenesis, metastasis, and tumor relapse, we could imagine, although the precise molecular mechanisms have not been elucidated, that EV could have an antitumoral action on cancer lung cells too [17]. Indeed, Takano et al. reported that strong nectin-4 expression revealed shorter survival periods and that serum nectin-4 positivity was independent prognostic factor for the patients with advanced NSCLC [12]. Nevertheless, so far, no clinical trial has been published on the efficacy of EV on patients with lung cancer. Nevertheless, a phase 2 clinical trial (EV-202) investigating the antitumor activity of EV on squamous NSCLC (objective response rate as the primary purpose) is ongoing (NCT04225117, estimated study completion date September 2026) [18]. In patients with advanced urothelial cancer, EV-related adverse events were mainly dermatologic, nectin-4 expressing on epidermal keratinocytes and skin appendages. Grade ≥ 3 severity treatment-related adverse events occurring in ≥ 5% of patients treated with EV included maculopapular rash (7,4%) and fatigue (6.4%). Nevertheless, treatment-related skin reactions (all grade included) occurred in 43.9% of patients [14]. In the recent retrospective European multicenter real-world patient cohort published, skin toxicity was the second most common side effect (after peripheral sensory neuropathy) with grade ≥ 3 skin toxicity reported in 3.2% of patients. Any grade skin toxicity was reported in only 24.8% [15]. This lower rate of treatment-related skin toxicity than in the prospective EV-301 study is possibly being caused by the retrospective nature of the study. Although rare, potential severe and possibly fatal adverse reactions had always been described [14, 15, 19]. So far, in contrast to immunotherapy in patients with lung cancer, no relationship between adverse events occurrence and treatment efficacy has been established or even studied [20]. It would be interesting to investigate whether normal skin nectin-4 expression correlates with tumor overexpression. This reported case of concomitant urothelial and lung (adeno)carcinoma successfully managed with an antibody–drug conjugate (ADC) represents an excellent sneak preview to an approved future use to EV on lung cancer. Obviously, observations in more patients will be required and are precisely in process on EV-202 clinical trial. Acknowledgements The authors have no acknowledgements to declare. Abbreviations Enfortumab vedotin Eastern Cooperative Oncology Group Performance Status Area under the curve Response Evaluation Criteria in Solid Tumors Computed tomography Marketing authorization Non-small cell lung cancer Progression-free survival Antibody–drug conjugate Author contributions MR and LV analyzed and interpreted the patient data. LV wrote the manuscript. All authors read and approved the manuscript. Funding This manuscript did not receive any funding. Availability of data and materials All data can be found at the department of medical oncology of Institut du Cancer Avignon-Provence from Avignon. Declarations Ethics approval and consent to participate Ethical approval was not necessary as this is a case study. Consent for publication Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal. Competing Interests The authors have no conflicts of interest to declare. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Data Availability Statement All data can be found at the department of medical oncology of Institut du Cancer Avignon-Provence from Avignon.